首页 > 最新文献

Radiology. Imaging cancer最新文献

英文 中文
Impact of PI-RADS Upgrading Rules on Prostate Cancer Detection and Biopsy Decision-Making. PI-RADS 升级规则对前列腺癌检测和活检决策的影响。
IF 5.6 Q1 ONCOLOGY Pub Date : 2024-03-01 DOI: 10.1148/rycan.249006
Yuan-Mao Lin
{"title":"Impact of PI-RADS Upgrading Rules on Prostate Cancer Detection and Biopsy Decision-Making.","authors":"Yuan-Mao Lin","doi":"10.1148/rycan.249006","DOIUrl":"10.1148/rycan.249006","url":null,"abstract":"","PeriodicalId":20786,"journal":{"name":"Radiology. Imaging cancer","volume":"6 2","pages":"e249006"},"PeriodicalIF":5.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10988339/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140132464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
It's Complicated: Managing Nonmass Enhancement Found at Breast MRI in Patients with Newly Diagnosed Cancer. 情况复杂:处理新确诊癌症患者在乳腺磁共振成像中发现的非质量增强。
IF 5.6 Q1 ONCOLOGY Pub Date : 2024-03-01 DOI: 10.1148/rycan.240003
Mary S Newell
{"title":"It's Complicated: Managing Nonmass Enhancement Found at Breast MRI in Patients with Newly Diagnosed Cancer.","authors":"Mary S Newell","doi":"10.1148/rycan.240003","DOIUrl":"10.1148/rycan.240003","url":null,"abstract":"","PeriodicalId":20786,"journal":{"name":"Radiology. Imaging cancer","volume":"6 2","pages":"e240003"},"PeriodicalIF":5.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10988333/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139672532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Prevalence and Radiologic Features of Renal Cancers Associated with FLCN, BAP1, SDH, and MET Germline Mutations. 与 FLCN、BAP1、SDH 和 MET 基因突变相关的肾癌的患病率和放射学特征
IF 5.6 Q1 ONCOLOGY Pub Date : 2024-03-01 DOI: 10.1148/rycan.230063
Charlotte Charbel, Pamela I Causa Andrieu, Mohamed Soliman, Sungmin Woo, Junting Zheng, Marinela Capanu, Ines Nikolovski, Hebert A Vargas, Murad Abusamra, Maria I Carlo

Purpose To investigate the prevalence of FLCN, BAP1, SDH, and MET mutations in an oncologic cohort and determine the prevalence, clinical features, and imaging features of renal cell carcinoma (RCC) associated with these mutations. Secondarily, to determine the prevalence of encountered benign renal lesions. Materials and Methods From 25 220 patients with cancer who prospectively underwent germline analysis with a panel of more than 70 cancer-predisposing genes from 2015 to 2021, patients with FLCN, BAP1, SDH, or MET mutations were retrospectively identified. Clinical records were reviewed for patient age, sex, race/ethnicity, and renal cancer diagnosis. If RCC was present, baseline CT and MRI examinations were independently assessed by two radiologists. Summary statistics were used to summarize continuous and categorical variables by mutation. Results A total of 79 of 25 220 (0.31%) patients had a germline mutation: FLCN, 17 of 25 220 (0.07%); BAP1, 22 of 25 220 (0.09%); SDH, 39 of 25 220 (0.15%); and MET, one of 25 220 (0.004%). Of these 79 patients, 18 (23%) were diagnosed with RCC (FLCN, four of 17 [24%]; BAP1, four of 22 [18%]; SDH, nine of 39 [23%]; MET, one of one [100%]). Most hereditary RCCs demonstrated ill-defined margins, central nonenhancing area (cystic or necrotic), heterogeneous enhancement, and various other CT and MR radiologic features, overlapping with the radiologic appearance of nonhereditary RCCs. The prevalence of other benign solid renal lesions (other than complex cysts) in patients was up to 11%. Conclusion FLCN, BAP1, SDH, and MET mutations were present in less than 1% of this oncologic cohort. Within the study sample size limits, imaging findings for hereditary RCC overlapped with those of nonhereditary RCC, and the prevalence of other associated benign solid renal lesions (other than complex cysts) was up to 11%. Keywords: Familial Renal Cell Carcinoma, Birt-Hogg-Dubé Syndrome, Carcinoma, Renal Cell, Paragangliomas, Urinary, Kidney © RSNA, 2024.

目的 调查肿瘤学队列中FLCN、BAP1、SDH和MET突变的发生率,并确定与这些突变相关的肾细胞癌(RCC)的发生率、临床特征和影像学特征。其次,确定所遇到的肾脏良性病变的患病率。材料与方法 从 2015 年至 2021 年期间对 25 220 名癌症患者进行了前瞻性种系分析,分析了 70 多个癌症易感基因,并回顾性地确定了 FLCN、BAP1、SDH 或 MET 基因突变的患者。对患者的年龄、性别、种族/民族和肾癌诊断进行了临床记录审查。如果存在 RCC,则由两名放射科医生独立评估基线 CT 和 MRI 检查结果。采用汇总统计法按突变对连续变量和分类变量进行汇总。结果 25 220 例患者中,共有 79 例(0.31%)发生了种系突变:其中,FLCN,25 220 例中有 17 例(0.07%);BAP1,25 220 例中有 22 例(0.09%);SDH,25 220 例中有 39 例(0.15%);MET,25 220 例中有 1 例(0.004%)。在这 79 例患者中,18 例(23%)被诊断为 RCC(FLCN,17 例中的 4 例 [24%];BAP1,22 例中的 4 例 [18%];SDH,39 例中的 9 例 [23%];MET,1 例中的 1 例 [100%])。大多数遗传性 RCC 表现为边缘不清、中央无强化区(囊性或坏死)、异质强化以及各种其他 CT 和 MR 放射学特征,与非遗传性 RCC 的放射学表现重叠。患者中其他良性肾实体病变(复杂囊肿除外)的发病率高达 11%。结论 在这组肿瘤患者中,FLCN、BAP1、SDH和MET突变的比例不到1%。在研究样本量限制范围内,遗传性RCC的成像结果与非遗传性RCC的成像结果重叠,其他相关良性实体肾病变(复杂囊肿除外)的发病率高达11%。关键词: 家族性肾细胞癌家族性肾细胞癌 Birt-Hogg-Dubé 综合征 癌症 肾细胞 副神经节瘤 泌尿 肾脏 © RSNA, 2024.
{"title":"The Prevalence and Radiologic Features of Renal Cancers Associated with <i>FLCN, BAP1, SDH</i>, and <i>MET</i> Germline Mutations.","authors":"Charlotte Charbel, Pamela I Causa Andrieu, Mohamed Soliman, Sungmin Woo, Junting Zheng, Marinela Capanu, Ines Nikolovski, Hebert A Vargas, Murad Abusamra, Maria I Carlo","doi":"10.1148/rycan.230063","DOIUrl":"10.1148/rycan.230063","url":null,"abstract":"<p><p>Purpose To investigate the prevalence of <i>FLCN, BAP1, SDH</i>, and <i>MET</i> mutations in an oncologic cohort and determine the prevalence, clinical features, and imaging features of renal cell carcinoma (RCC) associated with these mutations. Secondarily, to determine the prevalence of encountered benign renal lesions. Materials and Methods From 25 220 patients with cancer who prospectively underwent germline analysis with a panel of more than 70 cancer-predisposing genes from 2015 to 2021, patients with <i>FLCN, BAP1, SDH</i>, or <i>MET</i> mutations were retrospectively identified. Clinical records were reviewed for patient age, sex, race/ethnicity, and renal cancer diagnosis. If RCC was present, baseline CT and MRI examinations were independently assessed by two radiologists. Summary statistics were used to summarize continuous and categorical variables by mutation. Results A total of 79 of 25 220 (0.31%) patients had a germline mutation: <i>FLCN</i>, 17 of 25 220 (0.07%); <i>BAP1</i>, 22 of 25 220 (0.09%); <i>SDH</i>, 39 of 25 220 (0.15%); and <i>MET</i>, one of 25 220 (0.004%). Of these 79 patients, 18 (23%) were diagnosed with RCC (<i>FLCN</i>, four of 17 [24%]; <i>BAP1</i>, four of 22 [18%]; <i>SDH</i>, nine of 39 [23%]; <i>MET</i>, one of one [100%]). Most hereditary RCCs demonstrated ill-defined margins, central nonenhancing area (cystic or necrotic), heterogeneous enhancement, and various other CT and MR radiologic features, overlapping with the radiologic appearance of nonhereditary RCCs. The prevalence of other benign solid renal lesions (other than complex cysts) in patients was up to 11%. Conclusion <i>FLCN, BAP1, SDH</i>, and <i>MET</i> mutations were present in less than 1% of this oncologic cohort. Within the study sample size limits, imaging findings for hereditary RCC overlapped with those of nonhereditary RCC, and the prevalence of other associated benign solid renal lesions (other than complex cysts) was up to 11%. <b>Keywords:</b> Familial Renal Cell Carcinoma, Birt-Hogg-Dubé Syndrome, Carcinoma, Renal Cell, Paragangliomas, Urinary, Kidney © RSNA, 2024.</p>","PeriodicalId":20786,"journal":{"name":"Radiology. Imaging cancer","volume":"6 2","pages":"e230063"},"PeriodicalIF":5.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10988346/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140060372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Differentiating Benign from Malignant Cystic Renal Masses using CT Texture-based Machine Learning Algorithms. 利用基于 CT 纹理的机器学习算法区分良性和恶性囊性肾肿块
IF 5.6 Q1 ONCOLOGY Pub Date : 2024-03-01 DOI: 10.1148/rycan.249007
Anupama Ramachandran
{"title":"Differentiating Benign from Malignant Cystic Renal Masses using CT Texture-based Machine Learning Algorithms.","authors":"Anupama Ramachandran","doi":"10.1148/rycan.249007","DOIUrl":"10.1148/rycan.249007","url":null,"abstract":"","PeriodicalId":20786,"journal":{"name":"Radiology. Imaging cancer","volume":"6 2","pages":"e249007"},"PeriodicalIF":5.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10988326/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140185369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Highlighting the Benefits and Disadvantages of Individual Participant Data Meta-Analysis in Radiology. 突出放射学中个体参与者数据元分析的利弊。
IF 5.6 Q1 ONCOLOGY Pub Date : 2024-03-01 DOI: 10.1148/rycan.240018
Andre L F Costa, Sérgio L P C Lopes
{"title":"Highlighting the Benefits and Disadvantages of Individual Participant Data Meta-Analysis in Radiology.","authors":"Andre L F Costa, Sérgio L P C Lopes","doi":"10.1148/rycan.240018","DOIUrl":"10.1148/rycan.240018","url":null,"abstract":"","PeriodicalId":20786,"journal":{"name":"Radiology. Imaging cancer","volume":"6 2","pages":"e240018"},"PeriodicalIF":5.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10988325/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140060371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Percutaneous Microwave Ablation for Treatment of Retroperitoneal Tumors. 治疗腹膜后肿瘤的经皮微波消融术
IF 5.6 Q1 ONCOLOGY Pub Date : 2024-03-01 DOI: 10.1148/rycan.230080
Annika E Rossebo, Annie M Zlevor, Emily A Knott, Lu Mao, Allison B Couillard, Timothy J Ziemlewicz, J Louis Hinshaw, E Jason Abel, Meghan G Lubner, Erica M Knavel Koepsel, Shane A Wells, Lindsay M Stratchko, Paul F Laeseke, Fred T Lee

Purpose To determine if microwave ablation (MWA) of retroperitoneal tumors can safely provide high rates of local tumor control. Materials and Methods This retrospective study included 19 patients (median age, 65 years [range = 46-78 years]; 13 [68.4%] men and six [31.6%] women) with 29 retroperitoneal tumors treated over 22 MWA procedures. Hydrodissection (0.9% saline with 2% iohexol) was injected in 17 of 22 (77.3%) procedures to protect nontarget anatomy. The primary outcomes evaluated were local tumor progression (LTP) and complication rates. Oncologic outcomes, including overall survival (OS), progression-free survival (PFS), and treatment-free interval (TFI), were examined as secondary outcome measures. Results Median follow-up was 18 months (range = 0.5-113). Hydrodissection was successful in displacing nontarget anatomy in 16 of 17 (94.1%) procedures. The LTP rate was 3.4% (one of 29; 95% CI: 0.1, 17.8) per tumor and 5.3% (one of 19; 95% CI: 0.1, 26.0) per patient. The overall complication rate per patient was 15.8% (three of 19), including two minor complications and one major complication. The OS rate at 1, 2, and 3 years was 81.8%, 81.8%, and 72.7%, respectively, with a median OS estimated at greater than 7 years. There was no evidence of a difference in OS (P = .34) and PFS (P = .56) between patients with renal cell carcinoma (six of 19 [31.6%]) versus other tumors (13 of 19 [68.4%]) and patients treated with no evidence of disease (15 of 22 [68.2%]) versus patients with residual tumors (seven of 22 [31.8%]). Median TFI was 18 months (range = 0.5-108). Conclusion Treatment of retroperitoneal tumors with MWA combined with hydrodissection provided high rates of local control, prolonged systemic therapy-free intervals, and few serious complications. Keywords: Ablation Techniques (ie, Radiofrequency, Thermal, Chemical), Retroperitoneum, Microwave Ablation, Hydrodissection © RSNA, 2024.

目的 确定腹膜后肿瘤的微波消融 (MWA) 是否能安全地提供较高的局部肿瘤控制率。材料和方法 这项回顾性研究纳入了 19 名患者(中位年龄 65 岁 [范围 = 46-78 岁];13 名 [68.4%] 男性和 6 名 [31.6%] 女性),他们患有 29 例腹膜后肿瘤,接受了 22 次微波消融术治疗。在 22 例手术中,有 17 例(77.3%)注射了水切割液(0.9% 生理盐水加 2% 碘海醇),以保护非目标解剖结构。评估的主要结果是局部肿瘤进展(LTP)和并发症发生率。肿瘤学结果,包括总生存期(OS)、无进展生存期(PFS)和无治疗间隔期(TFI),则作为次要结果进行评估。结果 中位随访时间为 18 个月(范围 = 0.5-113)。在 17 例手术中,有 16 例(94.1%)的水切割成功移除了非目标解剖结构。每个肿瘤的 LTP 率为 3.4%(29 例中有 1 例;95% CI:0.1, 17.8),每个患者的 LTP 率为 5.3%(19 例中有 1 例;95% CI:0.1, 26.0)。每位患者的总并发症发生率为 15.8%(19 例中有 3 例),包括 2 例轻微并发症和 1 例严重并发症。1年、2年和3年的OS率分别为81.8%、81.8%和72.7%,中位OS估计超过7年。没有证据表明,肾细胞癌患者(19 例中的 6 例 [31.6%])与其他肿瘤患者(19 例中的 13 例 [68.4%])、无疾病证据患者(22 例中的 15 例 [68.2%])与残留肿瘤患者(22 例中的 7 例 [31.8%])之间的 OS(P = .34)和 PFS(P = .56)存在差异。中位 TFI 为 18 个月(范围 = 0.5-108)。结论 采用MWA联合水动力切除术治疗腹膜后肿瘤,局部控制率高,无系统治疗间隔时间长,严重并发症少。关键词消融技术(即射频、热、化学)、腹膜后、微波消融、水切割 © RSNA, 2024.
{"title":"Percutaneous Microwave Ablation for Treatment of Retroperitoneal Tumors.","authors":"Annika E Rossebo, Annie M Zlevor, Emily A Knott, Lu Mao, Allison B Couillard, Timothy J Ziemlewicz, J Louis Hinshaw, E Jason Abel, Meghan G Lubner, Erica M Knavel Koepsel, Shane A Wells, Lindsay M Stratchko, Paul F Laeseke, Fred T Lee","doi":"10.1148/rycan.230080","DOIUrl":"10.1148/rycan.230080","url":null,"abstract":"<p><p>Purpose To determine if microwave ablation (MWA) of retroperitoneal tumors can safely provide high rates of local tumor control. Materials and Methods This retrospective study included 19 patients (median age, 65 years [range = 46-78 years]; 13 [68.4%] men and six [31.6%] women) with 29 retroperitoneal tumors treated over 22 MWA procedures. Hydrodissection (0.9% saline with 2% iohexol) was injected in 17 of 22 (77.3%) procedures to protect nontarget anatomy. The primary outcomes evaluated were local tumor progression (LTP) and complication rates. Oncologic outcomes, including overall survival (OS), progression-free survival (PFS), and treatment-free interval (TFI), were examined as secondary outcome measures. Results Median follow-up was 18 months (range = 0.5-113). Hydrodissection was successful in displacing nontarget anatomy in 16 of 17 (94.1%) procedures. The LTP rate was 3.4% (one of 29; 95% CI: 0.1, 17.8) per tumor and 5.3% (one of 19; 95% CI: 0.1, 26.0) per patient. The overall complication rate per patient was 15.8% (three of 19), including two minor complications and one major complication. The OS rate at 1, 2, and 3 years was 81.8%, 81.8%, and 72.7%, respectively, with a median OS estimated at greater than 7 years. There was no evidence of a difference in OS (<i>P</i> = .34) and PFS (<i>P</i> = .56) between patients with renal cell carcinoma (six of 19 [31.6%]) versus other tumors (13 of 19 [68.4%]) and patients treated with no evidence of disease (15 of 22 [68.2%]) versus patients with residual tumors (seven of 22 [31.8%]). Median TFI was 18 months (range = 0.5-108). Conclusion Treatment of retroperitoneal tumors with MWA combined with hydrodissection provided high rates of local control, prolonged systemic therapy-free intervals, and few serious complications. <b>Keywords:</b> Ablation Techniques (ie, Radiofrequency, Thermal, Chemical), Retroperitoneum, Microwave Ablation, Hydrodissection © RSNA, 2024.</p>","PeriodicalId":20786,"journal":{"name":"Radiology. Imaging cancer","volume":"6 2","pages":"e230080"},"PeriodicalIF":5.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10988338/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139707640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluating the Use of ChatGPT to Accurately Simplify Patient-centered Information about Breast Cancer Prevention and Screening. 评估使用 ChatGPT 准确简化以患者为中心的乳腺癌预防和筛查信息。
IF 5.6 Q1 ONCOLOGY Pub Date : 2024-03-01 DOI: 10.1148/rycan.230086
Hana L Haver, Anuj K Gupta, Emily B Ambinder, Manisha Bahl, Eniola T Oluyemi, Jean Jeudy, Paul H Yi

Purpose To evaluate the use of ChatGPT as a tool to simplify answers to common questions about breast cancer prevention and screening. Materials and Methods In this retrospective, exploratory study, ChatGPT was requested to simplify responses to 25 questions about breast cancer to a sixth-grade reading level in March and August 2023. Simplified responses were evaluated for clinical appropriateness. All original and simplified responses were assessed for reading ease on the Flesch Reading Ease Index and for readability on five scales: Flesch-Kincaid Grade Level, Gunning Fog Index, Coleman-Liau Index, Automated Readability Index, and the Simple Measure of Gobbledygook (ie, SMOG) Index. Mean reading ease, readability, and word count were compared between original and simplified responses using paired t tests. McNemar test was used to compare the proportion of responses with adequate reading ease (score of 60 or greater) and readability (sixth-grade level). Results ChatGPT improved mean reading ease (original responses, 46 vs simplified responses, 70; P < .001) and readability (original, grade 13 vs simplified, grade 8.9; P < .001) and decreased word count (original, 193 vs simplified, 173; P < .001). Ninety-two percent (23 of 25) of simplified responses were considered clinically appropriate. All 25 (100%) simplified responses met criteria for adequate reading ease, compared with only two of 25 original responses (P < .001). Two of the 25 simplified responses (8%) met criteria for adequate readability. Conclusion ChatGPT simplified answers to common breast cancer screening and prevention questions by improving the readability by four grade levels, though the potential to produce incorrect information necessitates physician oversight when using this tool. Keywords: Mammography, Screening, Informatics, Breast, Education, Health Policy and Practice, Oncology, Technology Assessment Supplemental material is available for this article. © RSNA, 2023.

目的 评估将 ChatGPT 用作简化乳腺癌预防和筛查常见问题答案的工具的使用情况。材料和方法 在这项回顾性探索研究中,要求 ChatGPT 在 2023 年 3 月和 8 月将 25 个有关乳腺癌问题的回答简化为六年级的阅读水平。对简化后的回答进行了临床适宜性评估。根据 Flesch 阅读容易程度指数和五个量表对所有原始和简化回复的阅读容易程度进行了评估:弗莱什-金凯德等级水平、古宁雾指数、科尔曼-利亚指数、自动可读性指数和简单拗口指数(即 SMOG)。使用配对 t 检验比较了原始答案和简化答案的平均阅读难易度、可读性和字数。McNemar 检验用于比较具有适当阅读难度(60 分或以上)和可读性(六年级水平)的答卷比例。结果 ChatGPT 提高了平均阅读难度(原始答案 46 分,简化答案 70 分;P < .001)和可读性(原始答案 13 级,简化答案 8.9 级;P < .001),减少了字数(原始答案 193 字,简化答案 173 字;P < .001)。92%的简化回复(25 份中的 23 份)被认为符合临床需要。所有 25 份(100%)简化答卷都符合足够易读性的标准,而 25 份原始答卷中只有 2 份符合标准(P < .001)。25 个简化回复中有两个(8%)符合充分易读性标准。结论 ChatGPT 简化了常见的乳腺癌筛查和预防问题的答案,将可读性提高了四个等级,但由于可能会产生错误信息,因此医生在使用该工具时有必要进行监督。关键词乳房 X 线照相术 筛查 信息学 乳腺癌 教育 卫生政策与实践 肿瘤学 技术评估 本文有补充材料。© RSNA, 2023.
{"title":"Evaluating the Use of ChatGPT to Accurately Simplify Patient-centered Information about Breast Cancer Prevention and Screening.","authors":"Hana L Haver, Anuj K Gupta, Emily B Ambinder, Manisha Bahl, Eniola T Oluyemi, Jean Jeudy, Paul H Yi","doi":"10.1148/rycan.230086","DOIUrl":"10.1148/rycan.230086","url":null,"abstract":"<p><p>Purpose To evaluate the use of ChatGPT as a tool to simplify answers to common questions about breast cancer prevention and screening. Materials and Methods In this retrospective, exploratory study, ChatGPT was requested to simplify responses to 25 questions about breast cancer to a sixth-grade reading level in March and August 2023. Simplified responses were evaluated for clinical appropriateness. All original and simplified responses were assessed for reading ease on the Flesch Reading Ease Index and for readability on five scales: Flesch-Kincaid Grade Level, Gunning Fog Index, Coleman-Liau Index, Automated Readability Index, and the Simple Measure of Gobbledygook (ie, SMOG) Index. Mean reading ease, readability, and word count were compared between original and simplified responses using paired <i>t</i> tests. McNemar test was used to compare the proportion of responses with adequate reading ease (score of 60 or greater) and readability (sixth-grade level). Results ChatGPT improved mean reading ease (original responses, 46 vs simplified responses, 70; <i>P</i> < .001) and readability (original, grade 13 vs simplified, grade 8.9; <i>P</i> < .001) and decreased word count (original, 193 vs simplified, 173; <i>P</i> < .001). Ninety-two percent (23 of 25) of simplified responses were considered clinically appropriate. All 25 (100%) simplified responses met criteria for adequate reading ease, compared with only two of 25 original responses (<i>P</i> < .001). Two of the 25 simplified responses (8%) met criteria for adequate readability. Conclusion ChatGPT simplified answers to common breast cancer screening and prevention questions by improving the readability by four grade levels, though the potential to produce incorrect information necessitates physician oversight when using this tool. <b>Keywords:</b> Mammography, Screening, Informatics, Breast, Education, Health Policy and Practice, Oncology, Technology Assessment <i>Supplemental material is available for this article.</i> © RSNA, 2023.</p>","PeriodicalId":20786,"journal":{"name":"Radiology. Imaging cancer","volume":"6 2","pages":"e230086"},"PeriodicalIF":5.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10988327/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139672531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Low-Dose Positron Emission Mammography: A Novel, Promising Technique for Breast Cancer Detection. 低剂量正电子发射乳腺放射摄影术:用于乳腺癌检测的一种新型、前景广阔的技术。
IF 5.6 Q1 ONCOLOGY Pub Date : 2024-03-01 DOI: 10.1148/rycan.240006
David S Barreto, Jocelyn A Rapelyea
{"title":"Low-Dose Positron Emission Mammography: A Novel, Promising Technique for Breast Cancer Detection.","authors":"David S Barreto, Jocelyn A Rapelyea","doi":"10.1148/rycan.240006","DOIUrl":"10.1148/rycan.240006","url":null,"abstract":"","PeriodicalId":20786,"journal":{"name":"Radiology. Imaging cancer","volume":"6 2","pages":"e240006"},"PeriodicalIF":5.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10988329/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139707639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Screening Breast MRI Effectively Detects Early-Stage Breast Cancer in High-Risk Patients without Prior History of Breast Cancer. 乳腺磁共振成像筛查能有效检测无乳腺癌病史的高危患者中的早期乳腺癌。
IF 5.6 Q1 ONCOLOGY Pub Date : 2024-03-01 DOI: 10.1148/rycan.249005
Brandon K K Fields, Bonnie N Joe
{"title":"Screening Breast MRI Effectively Detects Early-Stage Breast Cancer in High-Risk Patients without Prior History of Breast Cancer.","authors":"Brandon K K Fields, Bonnie N Joe","doi":"10.1148/rycan.249005","DOIUrl":"10.1148/rycan.249005","url":null,"abstract":"","PeriodicalId":20786,"journal":{"name":"Radiology. Imaging cancer","volume":"6 2","pages":"e249005"},"PeriodicalIF":5.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10988331/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139932641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
2023 Manuscript Reviewers: A Note of Thanks. 2023 审稿人:感谢信。
IF 4.4 Q1 ONCOLOGY Pub Date : 2024-03-01 DOI: 10.1148/rycan.240054
Curtis P Langlotz, Gary D Luker
{"title":"2023 Manuscript Reviewers: A Note of Thanks.","authors":"Curtis P Langlotz, Gary D Luker","doi":"10.1148/rycan.240054","DOIUrl":"10.1148/rycan.240054","url":null,"abstract":"","PeriodicalId":20786,"journal":{"name":"Radiology. Imaging cancer","volume":"6 2","pages":"e240054"},"PeriodicalIF":4.4,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10988324/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140132460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Radiology. Imaging cancer
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1